Annual Cash & Cash Equivalents
$7.44 M
+$1.20 M+19.18%
December 1, 2023
Summary
- As of February 8, 2025, DRMA annual cash & cash equivalents is $7.44 million, with the most recent change of +$1.20 million (+19.18%) on December 1, 2023.
- During the last 3 years, DRMA annual cash & cash equivalents has risen by +$6.91 million (+1302.36%).
- DRMA annual cash & cash equivalents is now -31.12% below its all-time high of $10.80 million, reached on December 31, 2021.
Performance
DRMA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$6.14 M
+$1.20 M+24.19%
September 1, 2024
Summary
- As of February 8, 2025, DRMA quarterly cash and cash equivalents is $6.14 million, with the most recent change of +$1.20 million (+24.19%) on September 1, 2024.
- Over the past year, DRMA quarterly cash and cash equivalents has dropped by -$1.29 million (-17.40%).
- DRMA quarterly cash and cash equivalents is now -51.25% below its all-time high of $12.60 million, reached on September 30, 2021.
Performance
DRMA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
DRMA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +19.2% | -17.4% |
| 3 y3 years | +1302.4% | -27.2% |
| 5 y5 years | +273.4% | -27.2% |
DRMA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -31.1% | +19.2% | -43.1% | +29.8% |
| 5 y | 5-year | -31.1% | +1302.4% | -51.3% | +1338.2% |
| alltime | all time | -31.1% | +1302.4% | -51.3% | +1338.2% |
Dermata Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $6.14 M(+24.2%) |
| Jun 2024 | - | $4.95 M(+4.5%) |
| Mar 2024 | - | $4.73 M(-36.4%) |
| Dec 2023 | $7.44 M(+19.2%) | $7.44 M(+12.2%) |
| Sep 2023 | - | $6.63 M(-21.4%) |
| Jun 2023 | - | $8.44 M(-3.7%) |
| Mar 2023 | - | $8.77 M(+40.5%) |
| Dec 2022 | $6.24 M | $6.24 M(-22.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $8.07 M(-24.1%) |
| Jun 2022 | - | $10.63 M(+29.8%) |
| Mar 2022 | - | $8.19 M(-24.1%) |
| Dec 2021 | $10.80 M(+1936.0%) | $10.80 M(-14.3%) |
| Sep 2021 | - | $12.60 M(+2850.2%) |
| Jun 2021 | - | $427.20 K(-67.9%) |
| Mar 2021 | - | $1.33 M(+150.8%) |
| Dec 2020 | $530.40 K(-73.4%) | $530.40 K |
| Dec 2019 | $1.99 M | - |
FAQ
- What is Dermata Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Dermata Therapeutics?
- What is Dermata Therapeutics annual cash & cash equivalents year-on-year change?
- What is Dermata Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Dermata Therapeutics?
- What is Dermata Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Dermata Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of DRMA is $7.44 M
What is the all time high annual cash & cash equivalents for Dermata Therapeutics?
Dermata Therapeutics all-time high annual cash & cash equivalents is $10.80 M
What is Dermata Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, DRMA annual cash & cash equivalents has changed by +$1.20 M (+19.18%)
What is Dermata Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of DRMA is $6.14 M
What is the all time high quarterly cash and cash equivalents for Dermata Therapeutics?
Dermata Therapeutics all-time high quarterly cash and cash equivalents is $12.60 M
What is Dermata Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, DRMA quarterly cash and cash equivalents has changed by -$1.29 M (-17.40%)